Annualized was found better than absolute risk reduction in the calculation of number needed to treat in chronic conditions

Journal of Clinical Epidemiology

Volumn 59, Issue 3, 2006, Pages 217-223

  Mayne, Tracy J ^a   Whalen, Edward ^a   Vu, An ^a  

^a PFIZER INC   (United States)

Author keywords

Absolute risk reduction; Annualized NNT; Confidence interval; NNT

Indexed keywords

ANTIHYPERTENSIVE AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; CALCULATION; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DYSLIPIDEMIA; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STROKE;

EID: 32644434423     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2005.07.006     Document Type: Article

References (16)

1. A. Laupacis, D.L. Sackett, and R.S. Roberts An assessment of clinically useful measures of the consequences of treatment N Engl J Med 318 1988 1728 1733
2. A.P. Grieve The number needed to treat: a useful clinical measure or a case of the Emperor's new clothes? Pharmaceut Stat 2 2003 87 102
3. R. Collins, R. Peto, S. MacMahon, P. Hebert, N.H. Fiebach, K.A. Eberlein, J. Godwin, N. Qizilbash, J.O. Taylor, and C.H. Hennekens Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiologic context [Review] Lancet 335 1990 827 838
4. S.V. Rajkumar, P. Sampathkumar, and A.B. Gustafson Number needed to treat is a simple measure of treatment efficacy for clinicians J Gen Intern Med 11 1996 357 359
5. Scandinavian Simvastatin Survival Study Group [SSSSG] Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1995 1383 1389
6. D.M. Bell Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes Pharmacotherapy 19 1999 1086 1093
7. C.M. Rembold Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy J Fam Pract 42 1996 577 586
8. F. Van de Werf Mortality results in GUSTO Aust N Z J Med 23 1993 732 734
9. J.A. Skolbekken Communicating the risk reduction achieved by cholesterol reducing drugs [Review] BMJ 316 1998 1956 1958
10. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. MacFarlane, J.H. McKillop, and C.J. Packard West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
11. K.A. Pearce, C.D. Furberg, B.M. Psaty, and J. Kirk Cost-minimization and the number needed to treat in uncomplicated hypertension Am J Hypertens 11 1998 618 629
12. S.D. Walter Number needed to treat (NNT): estimation of a measure of clinical benefit Stat Med 20 2001 3947 3962
13. R. Bender Calculating confidence intervals for the number needed to treat Control Clin Trials 22 2001 102 110
14. J. Sun, and P.X.K. Song Statistical analysis of repeated measurements with informative censoring times Stat Med 20 2001 63 73
15. R.G. Newcombe Know your limitations: not just for clinicians: estimation of confidence intervals is not straightforward J Public Health Med 21 1999 481 482
16. P. Bickel, and K. Docksum Mathematical statistics 1977 Holden-Day San Francisco